Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The moon and sun figure big in the new year's lineup of cosmic wonders - 2Sean Penn lights up, Kylie Jenner gets A-list approval and 7 other moments you didn’t see at the Golden Globes
- 3Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
- 44 Jeep Models: Dominating Execution and Flexibility for Each Experience
- 5The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- The Best Internet based Courses for Expertise Improvement
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Iran’s Crown Prince Reza Pahlavi backs protests: Join your fellow citizens in the streets
- Geminid meteor shower, one of the year's most reliable, peaks this weekend
- Find the Future of Outsourcing: Exploring the Gig Economy
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
